Ensuring the Biologic Safety of Plasma-Derived Therapeutic Proteins
Authors:
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 19 (2) , 79-96
Abstract
Human plasma-derived proteins, such as immunoglobulins, coagulation factors, α1-antitrypsin, fibrin sealants, and albumin, are widely used as therapeutics for many serious and life-threatening medical conditions. The human origin of these proteins ensures excellent efficacy and compatibility but may also introduce the risk of unintentional disease transmission. Historically, only viruses, particularly hepatitis and HIV, have posed serious threats to the safety of these therapeutics. Fortunately, between 1970 and 1990, the molecular biology of each of the major viruses was elucidated. These advances led to the development and implementation of effective donor screening tests, mainly based on immunoassays and nucleic acid testing, which resulted in a significant reduction of disease transmission risk. In addition, viral inactivation and removal steps were implemented and validated by manufacturers, further reducing the risk associated with known, as well as unidentified, viruses. Since the late 1990s, a different class of transmissible agent, referred to as prions, has been identified as a new risk for disease transmission. However, prion diseases are very rare, and prion transmission through plasma-derived proteins has not been reported to date. The prion-related risk is minimized by deferring donors with certain key risk factors, and by the manufacturing processes that are capable of removing prions. Advances in science and pathogen safety-related technology, compliance with good manufacturing practices by manufacturers, and increasingly stringent regulatory oversight, has meant that plasma-derived proteins have been developed into today’s highly effective therapeutics with very low risk of disease transmission.Keywords
This publication has 119 references indexed in Scilit:
- Solvent-dependent precipitation of prion proteinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2002
- Scrapie Removal using Planova®Virus Removal FiltersBiologicals, 2001
- International Standardization of Gene Amplification TechnologyBiologicals, 1998
- Determination of Adequate Moisture Content for Efficient Dry-Heat Viral Inactivation in Lyophilized Factor VIII by Loss on Drying and by Near Infrared SpectroscopyBiologicals, 1998
- Inactivation of hepatitis A virus in plasma products by vapor heatingTransfusion, 1997
- Epidemiology of Creutzfeldt-Jakob Disease in the United States, 1979–1990: Analysis of National Mortality DataNeuroepidemiology, 1995
- THE TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIESAnnual Review of Medicine, 1995
- Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator GroupTransfusion, 1992
- Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B HepatitisNew England Journal of Medicine, 1989
- Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids1a,b,c,dJournal of the American Chemical Society, 1946